Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A methylxanthine with peripheral vasodilatory properties, reduction of blood viscosity and platelet antiaggregant, improving blood flow. It also inhibits the production of TNFα cytokine.
Indicated in chronic peripheral vascular obstruction of limbs. It has been used experimentally in maternal peripartum cardiomyopathy (Garg 2015), in sepsis, including neonatal (Tarnow 2010) and in necrotizing enterocolitis (Patole 2007).
Administered orally 3 times a day
It is excreted in breast milk in clinically negligible amounts (Witter 1985).
Possible side effects are not frequent.
When breastmilk freezes at -15º, pentoxifylline remains stable for 3 weeks (Bauza 1984).
There are very few bibliographical references. It is classified as having low therapeutic efficacy (Canary Islands Health Service 2011, INSALUD 2001).